HPV Aptima Positive or Negative: What the Result Means

At a Glance

The HPV Aptima assay is run on a cervical cell sample and reported as Positive or Negative — there is no number and no reference range.

What it looks for is specific. The FDA order statement for this assay, as amended in February 2026, describes it as a test "for the qualitative detection of E6/E7 viral messenger RNA (mRNA) from 14 high-risk types of human papillomavirus (HPV) in cervical specimens." The fourteen types are 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.

It has three labeled uses, and which one applies to you changes the question your result is answering. The same statement says the assay "is indicated for use for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (adjunctive screening) with cytology, and HPV primary screening of women to assess the risk for cervical pre-cancer and cancer." So it may be run after an abnormal Pap result, alongside a Pap, or as the primary screen on its own.

One sentence from the same statement governs what follows from any single result: "Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors."

So this is a screening result that informs risk, not a diagnosis. The sections below say what each of the two possible results does and does not mean, and much of the page is about the limits.

What the test detects, exactly

Three details in the approval wording do real work for a reader.

It detects mRNA, not DNA. The target is E6/E7 viral messenger RNA. DNA tests look for the virus being present; this one looks for two specific viral genes being transcribed.

It covers fourteen high-risk types and no others. The list above is the whole list. Types outside it are not what this assay reports on.

It cannot tell you which of the fourteen you have. The order statement is explicit: the assay "does not differentiate between the 14 high-risk types." A positive result names a group, not a type. That is why separate genotype tests for HPV 16 and for HPV 18/45 exist and may appear on the same report — they answer the question this test is not built to answer.

Why those two genes. LOINC's description of this test's code explains what makes E6 and E7 worth detecting: they "are known as oncogenes because of their continuous expression, which leads to disruption of cell-cycle check points and cell genome instability through alteration of cellular p53 and retinoblastoma protein functions." Detecting their mRNA is detecting that those genes are being expressed.

The specimen is also specified: cervical samples collected in ThinPrep Pap Test vials containing PreservCyt solution, using a broom-type or cytobrush and spatula device. A Pap result may sit beside yours on the report, or may not — under the primary-screening indication the HPV result stands on its own, and primary screening "has only been validated on the Panther System."

How to read your result

Negative. No E6/E7 mRNA from the fourteen high-risk types was detected in the sample. That is the reassuring result, and it is not a guarantee. The National Cancer Institute states plainly that "screening test results may appear normal even though cervical precancer or cancer is present." A negative result also says nothing about HPV types outside the fourteen, and nothing about a future sample.

Positive. E6/E7 mRNA from at least one of the fourteen high-risk types was detected. This is not a diagnosis of cervical precancer or cancer — but it is not nothing either. The label's own purpose for the test includes assessing "the risk for cervical pre-cancer and cancer", so a positive result is information about risk that a clinician acts on. It does not say which type, how long it has been there, or whether it will cause any change to your cells.

If your result is displayed as "abnormal" or "out of range", that is how a positive is flagged against a reference value of negative. The meaning is the one in the paragraph above: something was detected. It is not a measure of how much, or of how serious.

Either result, read with the rest of the report. The labeling directs that patients be followed up "in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors" — and little of that sits on your report. What follows from a result belongs with whoever ordered the test.

If you remember only one thing

A positive HPV Aptima result means a high-risk HPV type is present and active in that sample. It is not cancer, it is not a diagnosis, and it does not name the type. The US Preventive Services Task Force records that "a large proportion of HPV infections resolve spontaneously" — so a positive result is a reason to follow up, not a verdict.

Two people, same result

Two people are each told their HPV Aptima result is Positive. The same word is doing different jobs, because the assay has three labeled uses.

The first had an abnormal Pap first — a cytology result of ASC-US, atypical squamous cells of undetermined significance — and the HPV test was run to triage it. Here the positive result is adding information to a finding that already existed.

The second had no Pap at all. Her HPV test was the primary screen, which the February 2026 labeling added as an indication in its own right. Here the positive result is the first finding, and there is no cytology result beside it to read it against.

Same result word, two different situations, and the information available to interpret it differs between them. Neither person has been given a diagnosis. What each does next depends, in the label's own words, on "professional medical guidelines, results from prior screening, medical history, and other risk factors" — which is a clinical conversation rather than something a page can supply.

What this result cannot tell you

It cannot tell you which type you have — the assay does not differentiate between the fourteen.

It cannot tell you how long the virus has been there, or whether this is new. A single positive result has no time dimension.

It cannot tell you whether it will clear. USPSTF records that a large proportion of HPV infections resolve on their own, and also warns that "treatment of lesions that would otherwise resolve on their own is harmful" — which is part of why a single result does not drive action by itself.

It cannot establish whether you have cervical precancer or cancer. It detects high-risk HPV mRNA, and the label's stated purpose is to help assess the risk of precancer and cancer and to inform follow-up. Those are different things: the result contributes to a risk assessment and does not make a diagnosis.

It cannot rule HPV out completely when negative, for the reason the National Cancer Institute gives above, and it says nothing about types outside the fourteen.

It cannot say which of its three uses yours was. Triage of an abnormal Pap, co-testing alongside a Pap, and primary screening are different situations with different information available, and the result reads differently in each. Your report and whoever ordered the test know which applies.

Common interpretation mistakes

Reading a positive result as a cancer diagnosis. It reports detection of viral mRNA in a sample, which informs a risk assessment rather than establishing a diagnosis. The opposite mistake matters too: it is not a result to set aside.

Reading a negative result as proof nothing is there. The National Cancer Institute's sentence about normal-looking screening results is the direct answer to that, and the fourteen types are not all types.

Assuming the result names your HPV type. It cannot. If your report also lists HPV 16 or HPV 18/45 results, those came from different tests.

Treating "mRNA" as a claim about accuracy. It describes what the assay targets. Whether targeting mRNA performs better than targeting DNA is a separate question with its own evidence, discussed below rather than assumed.

Comparing this result to a different HPV test's result. Different assays target different things and report on different type sets.

Assuming one result settles the question. The labeling directs follow-up according to professional medical guidelines, prior screening results, medical history and other risk factors — a single result is one of those inputs.

Questions your doctor may ask

Whether a cervical cytology result was reported on the same sample, and what it was — some uses of this assay pair it with a Pap and primary screening does not. Whether HPV genotype results for 16 or 18/45 were reported alongside it. Whether you have had HPV testing before, and what it showed, since the label names results from prior screening as part of follow-up. And whether you have any condition affecting your immune system, since USPSTF excludes several such groups from its screening recommendation and directs that they "should receive individualized follow-up."

Read together with

HPV Genotype 16 and HPV Genotype 18,45 — the reflex genotype tests that answer the question this assay cannot, which of the fourteen types is present. PapIG, HPV, rfx 16/18 and HPV (Human Papillomavirus) may also appear on a report from the same sample. The cervical cytology result is the companion the approval wording names explicitly.

Clinical pearls

The mRNA-versus-DNA question, with its evidence stated rather than assumed. A 2026 prospective study compared an E6/E7 mRNA-plus-cytology strategy against a DNA-plus-cytology strategy for detecting high-grade squamous intraepithelial lesions, and reported sensitivity 77.97% and specificity 86.37% for the mRNA strategy against 72.09% and 83.05% for the DNA strategy. The authors' own wording is that the mRNA strategy "appeared higher" — and it assigned participants by preference rather than at random, recruited from gynecology outpatient clinics rather than a screening population, compared strategies rather than assays, and did not test this assay. A 2025 multicenter study that did test this assay reports its measured sensitivities as "comparable to HPV DNA sensitivities reported in similar populations" — so on the evidence that bears on this assay specifically, the question is open rather than settled in mRNA's favor.

The indications on this page are the current ones, and they changed recently. FDA approved supplement P100042/S038 on 3 February 2026 — a Panel Track supplement whose stated reason was a labeling change to indications — which added HPV primary screening and removed the age-banded framing of the 2011 original. Anything written about this assay before February 2026, including older explainers, may still describe it as a test that only accompanies cytology.

A screening guideline's scope is narrower than "anyone who had the test". USPSTF's cervical screening recommendation applies to "all asymptomatic individuals with a cervix" and explicitly "does not apply to women who have been diagnosed with a high-grade precancerous cervical lesion or cervical cancer."

Bodies differ on when screening should start. The National Cancer Institute records that the American Cancer Society recommends beginning at 25 with an HPV test, which differs from the USPSTF framing. Which applies to you is a clinical question.

Clinical Takeaway

Negative means no E6/E7 mRNA from the fourteen high-risk types was found in that sample, with the National Cancer Institute's caveat that a normal-looking screening result does not exclude precancer or cancer. Positive means at least one of the fourteen was found and being expressed — not which one, not for how long, and not a diagnosis, though it is information about risk that a clinician acts on. The label directs that patients be followed up according to professional medical guidelines, prior screening results, medical history and other risk factors, and a large proportion of HPV infections resolve without treatment. What that adds up to for you is not something a page can work out, and it is not something to put off.

In one sentence

HPV Aptima reports whether messenger RNA from any of fourteen high-risk HPV types was detected in a cervical sample, without saying which type — and it is a risk-assessment result, read against your history and whatever else was tested rather than on its own.

Bottom line

Positive means a high-risk HPV type was detected and being expressed — not that you have cancer, and not which type. Negative lowers the concern without eliminating it. Both are inputs into a risk assessment that needs the rest of your history, and both are worth a conversation rather than a conclusion.

HPV Aptima

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →

Beyond HPV Aptima — 10,000+ markers explained

One HPV Aptima result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.

Start with this report →

Frequently Asked Questions